Integrating Humanized Models Research Bridging Gap Between

In the field of laboratory animal science, humanized models are
revolutionizing biomedical research, offering a transformative approach
to bridging the gap between preclinical and clinical studies. By
integrating human cells, tissues, or genes into laboratory animals,
particularly immunodeficient mice, researchers can study human-specific
diseases and responses in a controlled environment. This development has
significantly enhanced the predictive accuracy of preclinical findings
and their applicability to human health, improving therapeutic outcomes
and advancing precision medicine.

Humanized models represent a critical evolution in research
methodologies, providing unparalleled insights into human biological
processes. Unlike traditional models, which often fail to replicate the
complexities of human genetics and physiology, these models enable a
more accurate representation of human diseases and drug responses (Choo
& Salphati, 2018; Yang et al., 2023; Walsh et al., 2017). Their creation
involves advanced techniques such as gene editing with CRISPR, cellular
engraftment using human stem cells or tissues, and immune system
humanization with human hematopoietic stem cells.

Bridging Preclinical and Clinical Studies

Humanized models serve as a vital bridge between preclinical and
clinical research. By closely mimicking human biology, they allow for
the evaluation of drug efficacy, safety, and immunological responses in
a context directly applicable to human patients. For example, in cancer
research, humanized models, such as patient-derived xenografts (PDX),
have facilitated a deeper understanding of tumor growth, immune system
interactions, and treatment responses, contributing to advancements in
immunotherapies (Yang et al., 2023; Shultz et al., 2019; Huilin et al.,
2020). Similarly, these models have been pivotal in studying human
immune responses, essential for developing precision medicine strategies
tailored to specific patient needs (Saito et al., 2020).

Impact on Research Methodologies

The adoption of humanized models has significantly influenced research
approaches, enhancing the translational potential of preclinical
studies. Researchers have gained unprecedented opportunities to
investigate complex disease mechanisms, including those underlying
cancer, infectious diseases, autoimmune disorders, and neurological
conditions (Walsh et al., 2017; Gbyli et al., 2020; Guo et al., 2024).
Humanized liver models, for instance, have advanced our understanding of
drug metabolism, improving predictions of drug safety and efficacy in
humans.

Moreover, these models align with ethical research principles,
supporting the 3Rs (Replacement, Reduction, Refinement) by refining
experiments to generate human-relevant data and potentially reducing the
need for extensive human trials. This ethical alignment underscores
their growing role in shaping the future of biomedical research.

Challenges and Future Directions

Despite their transformative potential, humanized models face
challenges. Their development is labor-intensive, resource-demanding,
and costly. Additionally, the incomplete replication of human physiology
in these models poses limitations, requiring careful interpretation of
experimental data. Ethical considerations surrounding the integration of
human cells into animals further complicate their use.

Looking ahead, research aims to refine these models to better mimic
human biology, leveraging advances in stem cell technology, gene
editing, and artificial intelligence (AI). Integrating humanized models
with AI and digital twins holds promise for enhancing predictive
accuracy and accelerating drug discovery. Expanding the repertoire of
disease models, particularly for rare and complex conditions, will
further broaden their utility. Global collaborations will also play a
key role in making these sophisticated tools more accessible and
impactful.

A New Era of Research

Humanized models are at the forefront of a new era in laboratory animal
science, bridging preclinical and clinical research with unparalleled
precision. Their continued development promises to deepen our
understanding of human diseases, optimize drug development pipelines,
and drive innovations in personalized medicine. As the scientific
community embraces these advancements, the integration of humanized
models will undoubtedly redefine the boundaries of biomedical research.

Share Your Insights 💬

How have humanized models influenced your research or clinical practice?
Share your experiences and perspectives on their transformative
potential. Let\’s drive the conversation forward and explore the future
of these groundbreaking tools! 🚀

————————————————————————

References

– Choo, E., & Salphati, L. (2018). Leveraging Humanized Animal Models

to Understand Human Drug Disposition: Opportunities, Challenges, and
Future Directions. Clinical Pharmacology & Therapeutics, 103.

– Yang, Y., Li, J., Li, D., Zhou, W., Yan, F., & Wang, W. (2023).

Humanized mouse models: A valuable platform for preclinical
evaluation of human cancer. Biotechnology and Bioengineering, 121,
835–852.

– Walsh, N., Kenney, L., Jangalwe, S., Aryee, K., Greiner, D., Brehm,

M., & Shultz, L. (2017). Humanized Mouse Models of Clinical Disease.
Annual Review of Pathology, 12, 187–215.

– Nieto, S., Grodin, E., Aguirre, C., Izquierdo, A., & Ray, L. (2021).

Translational opportunities in animal and human models to study
alcohol use disorder. Translational Psychiatry, 11.

– Shultz, L., Keck, J., Burzenski, L., Jangalwe, S., Vaidya, S.,

Greiner, D., & Brehm, M. (2019). Humanized mouse models of
immunological diseases and precision medicine. *Mammalian Genome,
30,* 123–142.

– Brubaker, D., & Lauffenburger, D. (2020). Translating preclinical

models to humans. Science, 367, 742–743.

– Saito, Y., Shultz, L., & Ishikawa, F. (2020). Understanding Normal

and Malignant Human Hematopoiesis Using Next-Generation Humanized
Mice. Trends in Immunology.

– Gbyli, R., Song, Y., & Halene, S. (2020). Humanized mice as

preclinical models for myeloid malignancies. *Biochemical
Pharmacology, 113794.*

– Guo, H., Xu, X., Zhang, J., Du, Y., Yang, X., He, Z., Zhao, L.,

Liang, T., & Guo, L. (2024). The Pivotal Role of Preclinical Animal
Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy
Strategies. Pharmaceuticals, 17.